RT Journal Article
SR Electronic
T1 Emergence of a novel reassortant Oropouche virus drives persistent human outbreaks in the Brazilian Amazon region from 2022 to 2024
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.23.24310415
DO 10.1101/2024.07.23.24310415
A1 Naveca, Felipe Gomes
A1 de Almeida, Tatiana Amaral Pires
A1 Souza, Victor
A1 Nascimento, Valdinete
A1 Silva, Dejanane
A1 Nascimento, Fernanda
A1 Mejía, Matilde
A1 de Oliveira, Yasmin Silva
A1 Rocha, Luisa
A1 Xavier, Natana
A1 Lopes, Janis
A1 Maito, Rodrigo
A1 Meneses, Cátia
A1 Amorim, Tatyana
A1 Fé, Luciana
A1 Camelo, Fernanda Sindeaux
A1 Silva, Samyly Coutinho de Aguiar
A1 de Melo, Alexsandro Xavier
A1 Fernandes, Leíse Gomes
A1 de Oliveira, Marco Aurélio Almeida
A1 Arcanjo, Ana Ruth
A1 Araújo, Guilherme
A1 André Júnior, Walter
A1 de Carvalho, Renata Lia Coragem
A1 Rodrigues, Rosiane
A1 Albuquerque, Stella
A1 Mattos, Cristiane
A1 Silva, Ciciléia
A1 Linhares, Aline
A1 Rodrigues, Taynã
A1 Mariscal, Francy
A1 Morais, Márcia Andréa
A1 Presibella, Mayra Marinho
A1 Marques, Nelson Fernando Quallio
A1 Paiva, Anne
A1 Ribeiro, Karina
A1 Vieira, Deusilene
A1 Queiroz, Jackson Alves da Silva
A1 Passos-Silva, Ana Maísa
A1 Abdalla, Lígia
A1 Santos, João Hugo
A1 de Figueiredo, Regina Maria Pinto
A1 Cruz, Ana Cecília Ribeiro
A1 Casseb, Livia Neves
A1 Chiang, Jannifer Oliveira
A1 Frutuoso, Livia Vinhal
A1 Rossi, Agata
A1 Freitas, Lucas
A1 Campos, Túlio de Lima
A1 Wallau, Gabriel Luz
A1 Moreira, Emerson
A1 Neto, Roberto Dias Lins
A1 Alexander, Laura W.
A1 Sun, Yining
A1 de Filippis, Ana Maria Bispo
A1 Gräf, Tiago
A1 Arantes, Ighor
A1 Bento, Ana I.
A1 Delatorre, Edson
A1 Bello, Gonzalo
YR 2024
UL http://medrxiv.org/content/early/2024/07/24/2024.07.23.24310415.abstract
AB The Brazilian western Amazon region is currently experiencing its largest laboratory confirmed Oropouche virus (OROV) outbreak, with nearly 6,000 reported cases in the states of Amazonas (AM), Acre (AC), Rondônia (RO), and Roraima (RR), between August 2022 and March 2024. Here, we sequenced and analyzed 382 full-length OROV genomes from human samples collected between 2022 and 2024 from all four states, aiming to trace the origin and genetic evolution of OROV leading to the current outbreak. Genomic analyses revealed that the recent upsurge of OROV cases in the Brazilian Amazon region coincides with the emergence of a novel reassortant viral lineage containing the M segment of viruses detected in the eastern Amazon region from 2009 to 2018 and the L and S segments of viruses detected in Peru, Colombia, and Ecuador from 2008 to 2021. The novel reassortant OROV lineage likely emerged in the Central region of the AM state between 2010 and 2014 and displayed a long-range silent dispersion during the second half of the 2010s. The 2022-2024 OROV epidemic was spatially segregated into three major subpopulations located in RR, AMACRO (a bordering region between AC, RO, and AM-Southern region), and AM-Central (which includes the Amazonas’ capital, Manaus) regions. The peak of OROV transmissions in all regions occurred during the rainy season in the Amazon basin. Furthermore, our phylodynamics reconstructions showed that OROV spread was driven mainly by short-range (< 2 km) movements, with an average dispersal rate ≤ 1.2 km/day, consistent with the pattern of an active flight of infected vectors. Nevertheless, a substantial proportion (22%) of long-range (> 10 km) OROV migrations were also detected, consistent with viral dispersion via human activities. Our data provides an unprecedented view of the real-time spread and evolution of a neglected emergent human pathogen. Moreover, our results emphasize the need for widespread, long-term genomic surveillance to better understand the real burden of OROV within and beyond the Amazon region.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding support FAPEAM Call 04/2022/FIOCRUZ/FAPEAM/FAPERO INOVACAO NA AMAZONIA; Amazonia +10; FAPEAM Call 023/2022 INICIATIVA AMAZONIA +10; Inova Fiocruz Inova Amazonia; Rede Genomica de Vigilancia em Saude do Estado do Amazonas REGESAM (Resolucao n 002/2008, 007/2018 e 005/2019 PRO-ESTADO/FAPEAM); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico CNPq Institutos Nacionais de Ciencia e Tecnologia (INCT VER) e Chamada CNPq/MCTI 10/2023 - Faixa B Grupos Consolidados Universal 2023 (421620/2023-4). GLW and GB are supported by the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) through their productivity research fellowships (307209/2023-7 and 304883/2020-4). ED and AR are supported by Fundacao de Amparo a Pesquisa e Inovacao do Espirito Santo (FAPES).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of Amazonas State University (CAAE: 72678923.8.0000.5016), which waived signed informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll the OROV genomes generated and analyzed in this study were deposited at GenBank under accession numbers PP153945 to PP154172 and PQ064571 to PQ065491.